For a patient otherwise suitable for APBI, would neoadjuvant endocrine therapy administered for extemporizing reasons (e.g., COVID diagnosis and recovery, rather than downstaging) preclude consideration of APBI?  

Answer from: Radiation Oncologist at Academic Institution
Radiation Oncologist at Washington University School of Medicine
I agree with @Chirag S. Shah (always a good option...
Sign in or Register to read more